ClinicalTrials.gg
CompletedNCT01598844JUPITERUpdated Nov 24, 2020

JUPITER Study: Transapical Aortic Valve Implantation for Aortic Regurgitation

An observational study in Aortic Stenosis, Aortic Insufficiency and Aortic Regurgitation, sponsored by JenaValve Technology, Inc.. Completed at 15 sites in 4 countries. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by JenaValve Technology, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
210
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.

Enrollment
61st of 98
210 · median 300
Started
2012
with 9 others
Observational
98 of 191
22 open now
Registered
29th of 191
by date

Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 61st largest by enrollment of the 98 observational ones that give a count, is one of 10 that started in 2012, is one of 98 observational ones, and was the 29th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Aortic Valve Stenosis with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this registry is to observe longterm performance and safety of the JenaValve TAVI system, in routine medical and everyday conditions.

Read the detailed description

The objective of this study is to evaluate the long term safety and effectiveness of the CE-marked JenaValve System Transapical in an elderly patient population with severe aortic stenosis and/or aortic insufficiency who are at high risk for open surgical aortic valve replacement.

The target study population will consist of elderly patients suffering from severe symptomatic degenerative aortic valve stenosis and/or aortic insufficiency who show an increased risk for an open aortic valve replacement surgery due to existing co-morbidities.

03

Conditions studied

  • Aortic Stenosis
  • Aortic Insufficiency
  • Aortic Regurgitation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with severe aortic stenosis or with severe aortic insufficiency and an increased risk for an open aortic valve replacement surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients suitable for TAVI with the JenaValve according to instructions for use

Exclusion criteria

Exclusion Criteria:

  • Patients unsuitable for TAVI with the JenaValve according to instructions for use
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
210 participants (actual)

Groups and cohorts

  • High risk patients with aortic stenosis

    Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.

    Device: Transcatheter aortic valve replacement

  • High risk patients with AI

    Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.

    Device: Transcatheter aortic valve replacement

Interventions

  • DeviceTranscatheter aortic valve replacement

    Transcatheter aortic valve replacement via a transapical access

    Also known as: The JenaValve TAVI System

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    30-day mortality of procedure is defined as all deaths within 30 days after implantation of the JenaValve prosthesis irrespective of the underlying cause of death.

    Time frame: 30 day

Secondary outcomes

  1. Safety Endpoints

    * All-cause mortality * Cardiovascular mortality * Major stroke * Life-threatening or disabling bleeding * Major bleeding * Acute kidney injury * Myocardial infarction * Major vascular complication * Mechanical coronary obstruction * Prosthetic valve thrombus * Prosthetic valve endocarditis * Conduction disturbance and cardiac arrhythmia * Necessity of permanent pacemaker implantation

    Time frame: peri- and post-operatively and at 3, 6, 12, 24 and 36 months

  2. Device Success

    The following parameters will be collected to assess device success: 1. Successful vascular access, delivery and deployment of the device successful retrieval of the device 2. Correct position of the device in the proper anatomical location 3. Intended performance of the prosthetic heart valve: 4. Only one valve implanted in proper anatomical position

    Time frame: Index Procedure and Immediate Post-operative

  3. Device Effectiveness

    The following parameters will assess effectiveness: * Transvalvular aortic peak pressure gradient * Transvalvular aortic mean pressure gradient * Effective aortic valve area * Paravalvular regurgitation coded according to VARC * Transvalvular regurgitation coded according to VARC * No clinically significant valve migration/dislocation * Absence of mechanical coronary obstruction * Functional improvement assessment by NYHA functional classification

    Time frame: Prior to discharge, at 3, 6, 12, 24 and 36 months

  4. SF-12 Survey of Quality of Life

    The SF-12 health survey to measure mental and physical health of the patient.

    Time frame: at 12 months

  5. Combined Safety Endpoint

    A combined safety endpoint will be assessed at 30 days consisting of the following variables: * All-cause mortality * Major stroke * Acute kidney injury (Stage 3) * Life-threatening or disabling bleeding * Major vascular complication * Peri-procedural myocardial infarction * Repeat surgical or interventional procedure for valve-related dysfunction

    Time frame: at 30 days

  6. Combined Efficacy Endpoint

    A combined efficacy endpoint will be assessed consisting of the following variables: * All-cause mortality (after \> 30 days) * Failure of current therapy for AS, requiring hospitalization for symptoms of valve-related or cardiac decompensation * Prosthetic heart valve dysfunction

    Time frame: at 12 months

07

Study locations

15 sites
  • Herz- und Diabeteszentrum NRW
    Bad Oeynhausen, Germany
  • Herzzentrum Dresden, Universitätsklinik an der Technischen Universität Dresden
    Dresden, Germany
  • University Hospital
    Erlangen, Germany
  • University Heart Centre
    Freiburg, Germany
  • Asklepios Klinik
    Hamburg, Germany
  • Universitäres Herzzentrum Hamburg
    Hamburg, Germany
  • Herzzentrum der Universität
    Köln, Germany
  • Herzzentrum Leipzig - Universitätsklinik
    Leipzig, Germany
  • Deutsches Herzzentrum München
    Munich, Germany
  • Herzzentrum des Städtischen Klinikums München
    Munich, Germany
  • Herz- und Kreislaufzentrum Rotenburg (Fulda)
    Rotenburg An Der Fulda, Germany
  • Robert Bosch Krankenhaus Stuttgart
    Stuttgart, Germany
  • St. Antonius Ziekenhuis
    Nieuwegein, Netherlands
  • Universitätsspital Basel
    Basel, Switzerland
  • King's College Hospital
    London, United Kingdom
08

References and documents

Publications

  • Mieres J, Menendez M, Fernandez-Pereira C, Rubio M, Rodriguez AE. Transapical Implantation of a 2nd-Generation JenaValve Device in Patient with Extremely High Surgical Risk. Case Rep Cardiol. 2015;2015:458151. doi: 10.1155/2015/458151. Epub 2015 Aug 4. PubMed 26346128 ↗
  • Seiffert M, Bader R, Kappert U, Rastan A, Krapf S, Bleiziffer S, Hofmann S, Arnold M, Kallenbach K, Conradi L, Schlingloff F, Wilbring M, Schafer U, Diemert P, Treede H. Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv. 2014 Oct;7(10):1168-74. doi: 10.1016/j.jcin.2014.05.014. Epub 2014 Aug 13. PubMed 25129672 ↗
  • Silaschi M, Treede H, Rastan AJ, Baumbach H, Beyersdorf F, Kappert U, Eichinger W, Ruter F, de Kroon TL, Lange R, Ensminger S, Wendler O. The JUPITER registry: 1-year results of transapical aortic valve implantation using a second-generation transcatheter heart valve in patients with aortic stenosis. Eur J Cardiothorac Surg. 2016 Nov;50(5):874-881. doi: 10.1093/ejcts/ezw170. Epub 2016 May 30. PubMed 27242354 ↗
  • Silaschi M, Conradi L, Wendler O, Schlingloff F, Kappert U, Rastan AJ, Baumbach H, Holzhey D, Eichinger W, Bader R, Treede H. The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. Catheter Cardiovasc Interv. 2018 Jun;91(7):1345-1351. doi: 10.1002/ccd.27370. Epub 2017 Nov 24. PubMed 29171730 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Aug 2015, 38 months.

Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 38 months is above that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2012
First posted
May 15, 2012
StartActual
May 30, 2012
Primary completionActual
Aug 27, 2015
CompletionActual
Jul 31, 2018
Last update
Nov 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01598844
Lead sponsor
JenaValve Technology, Inc.
Responsible party
Sponsor
First posted
May 15, 2012
Start date
May 30, 2012
Primary completion
Aug 27, 2015
Completion
Jul 31, 2018
Last update
Nov 24, 2020

Study contacts

Olaf Wendler, Prof
principal investigator · King's College Hospital NHS Trust
Hendrik Treede, Prof
principal investigator · University Heart Center Hamburg

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion